MedTrace Logo

Ascending-Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics of DC371739 Single-Dose Treatment in Healthy Subjects

NCT04640012 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 43

Last updated 2025-08-03

No results posted yet for this study

Summary

This study is to evaluate the safety, tolerability, pharmacokinetics of DC371739 after a single-dose oral administration in healthy Chinese subjects, and to explore the maximum tolerated dose, also the pharmacokinetics of urine and feces.

Conditions

Interventions

DRUG

DC371739

Participants received one of 6 dose levels of DC371739 administered as single oral doses.

DRUG

Placebo

Placebo orally administered

Sponsors & Collaborators

  • Guangzhou JOYO Pharma Co., Ltd

    lead INDUSTRY

Principal Investigators

  • Song Ai yun, Phd.MD. · Guang zhou JOYO Pharma

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
40 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2020-09-25
Primary Completion
2021-03-19
Completion
2022-03-15

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04640012 on ClinicalTrials.gov